1. Home
  2. IPHA

IPHA

Innate Pharma S.A. ADS

Logo Innate Pharma S.A. ADS

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Founded: 1999 Country:
France
France
Employees: N/A City: N/A
Market Cap: 203.7M IPO Year: 2019
Target Price: $11.50 AVG Volume (30 days): 10.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.10 EPS Growth: N/A
52 Week Low/High: $1.81 - $3.57 Next Earning Date: 03-21-2024
Revenue: $68,490,000 Revenue Growth: 149.53%
Revenue Growth (this year): -42.15% Revenue Growth (next year): 108.70%

Share on Social Networks: